Core Viewpoint - HengRui Pharma has entered into a collaboration agreement with GlaxoSmithKline (GSK) to co-develop up to 12 innovative drugs, which will enhance HengRui's globalization efforts and provide GSK with significant growth opportunities post-2031 [1] Group 1: Collaboration Details - The collaboration includes a total upfront payment of $500 million from GSK to HengRui [1][3] - HengRui will license its PDE3/4 inhibitor, HRS-9821, to GSK for global rights outside of Greater China, which is currently in clinical development for chronic obstructive pulmonary disease (COPD) [1][2] - The agreement also encompasses a groundbreaking collaborative plan to develop up to 11 additional projects, with HengRui leading the research and GSK having exclusive options for further development and commercialization [2][3] Group 2: Strategic Implications - The partnership is seen as a significant milestone in HengRui's internationalization process, leveraging GSK's strengths in drug development and global clinical networks to accelerate the entry of innovative therapies into overseas markets [2] - GSK's Chief Scientific Officer emphasized the strategic investment in validated target projects, which can significantly enhance the success rate of research and development [2] - The collaboration aims to integrate GSK's expertise in disease biology and clinical development with HengRui's capabilities in early-stage research and clinical evaluation, maximizing strategic synergies [2] Group 3: Financial Potential - If all projects are successfully developed and milestones are achieved, HengRui could qualify for potential milestone payments totaling approximately $12 billion [3] - HengRui will also be entitled to receive tiered sales royalties from GSK, excluding sales in Greater China [3]

Core Insights - Hengrui Pharma has entered into agreements with GSK to develop up to 12 innovative medicines, enhancing Hengrui's globalization strategy and providing new growth opportunities for GSK beyond 2031 [1][5] - GSK will pay $500 million in upfront fees for the agreements, which include a license for a potential best-in-class PDE3/4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease (COPD) [1][6] Group 1: Agreements and Financials - The agreements grant GSK an exclusive worldwide license for HRS-9821, aimed at treating COPD as an add-on maintenance treatment [2][8] - The total potential value of future success-based payments to Hengrui Pharma could reach approximately $12 billion if all programmes are optioned and milestones achieved [6] Group 2: Development and Collaboration - Hengrui Pharma will lead the development of the additional 11 programmes up to the completion of phase I trials, with GSK having the option to further develop and commercialize them [4][8] - The collaboration is expected to leverage GSK's R&D expertise and global clinical network, accelerating the development of innovative therapies [5][6]

中证指数有限公司与恒生指数有限公司公布沪港通AH股精明指数半年度指数检讨结果，将加入恒瑞医 药(01276.HK)与海天味业(03288.HK)；剔除东方证券(03958.HK)、广汽集团(02238.HK)。 相关链接 ...

Core Viewpoint - The Hong Kong stock market experienced a significant surge in IPO activities in the first half of 2025, driven by a strong participation of cornerstone investors, leading to a total of 42 IPOs that raised HKD 107.1 billion, marking a year-on-year increase of approximately 700% and positioning Hong Kong as the leading global market for IPO fundraising [1][2]. Group 1: IPO Market Performance - In the first half of 2025, Hong Kong's IPO market completed 42 IPOs, raising a total of HKD 107.1 billion, which is a 700% increase year-on-year and a 22% increase compared to the total amount raised in 2024 [1]. - Four out of the top ten global IPOs in 2025 were from Hong Kong, highlighting the city's growing prominence in the global IPO landscape [1]. - The participation of cornerstone investors was crucial, with 36 out of 42 IPOs attracting a total of 189 cornerstone investors, accounting for 85.71% of the IPOs [2]. Group 2: Characteristics of Cornerstone Investors - The cornerstone investment in Hong Kong's IPOs showed three notable trends: a significant clustering of investors, a preference for industry-leading companies, and impressive investment returns [2][4]. - A total of 452.02 million HKD in cornerstone investments represented over 42% of the total fundraising in the market, indicating strong confidence from capital sources [2]. - Leading companies such as Ningde Times, Haitian Flavoring, and Sanhua Intelligent Control attracted a total of 60 cornerstone investors, accounting for 31.7% of the total, with investment amounts reaching HKD 351.4 billion, which is over 77% of the total cornerstone investment [2][4]. Group 3: Investment Returns and Market Dynamics - As of July 15, 2025, 31 out of 36 IPOs with cornerstone investors saw their stock prices rise compared to their issue prices, with 21 companies experiencing price increases exceeding 50% [4]. - The diverse composition of cornerstone investors, including local state-owned platforms, foreign institutions, public funds, and individual investors, contributed to a robust market environment [5][10]. - The participation of foreign institutions in cornerstone investments has notably increased, with significant investments from entities like the Kuwait Investment Authority and the Singapore Government Investment Corporation [7][10]. Group 4: Sector Focus and Future Outlook - Cornerstone investors are primarily focusing on sectors such as new energy, consumer goods, pharmaceuticals, and advanced manufacturing, aligning with national industrial policies and market trends [10]. - The involvement of cornerstone investors is expected to stabilize new stock prices and build investor confidence, with major institutions playing a key role in reducing market volatility [10]. - Looking ahead, the Hong Kong IPO market is anticipated to attract more quality enterprises, with local state-owned enterprises and foreign institutions expected to deepen their involvement in cornerstone investments [10].

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a "valuation reversal," with H-shares transitioning from long-term discounts to premiums, particularly highlighted by the strong performance of leading innovative drug company Heng Rui Medicine, whose H-shares have shown a premium of over 20% compared to A-shares [1][4]. Group 1: Market Dynamics - The A+H pharmaceutical stocks have seen a significant shift in pricing logic, with the discount on Hong Kong stocks narrowing and some leading companies even turning to a premium [1][5]. - As of July 14, 2025, five companies, including Heng Rui Medicine, have reported positive premiums for their H-shares compared to A-shares, indicating a broader trend in the market [2][3]. - Heng Rui Medicine's H-shares have increased by over 29% since May 23, while A-shares have only risen by 10.19%, leading to a notable premium [4]. Group 2: Valuation Factors - The narrowing of discounts and the emergence of premiums in Hong Kong pharmaceutical stocks are attributed to the acceleration of innovation capabilities and the realization of value in the sector [7]. - The influx of southbound capital into Hong Kong stocks, particularly in leading companies like Heng Rui Medicine, has contributed to the narrowing of the long-standing price gap between A-shares and H-shares [7][8]. - The improvement of the Hong Kong Stock Connect mechanism has facilitated easier access for mainland institutional investors to invest in H-shares, enhancing liquidity and demand [8]. Group 3: Future Outlook - The trend indicates a potential long-term separation in the performance of H-shares, with companies that have strong internationalization and technological advantages likely to maintain premiums of 20%-30% [9][10]. - Companies that fail to innovate or adapt may face further valuation declines, leading to a market environment where stronger firms thrive while weaker ones are consolidated [9][10]. - The shift in valuation from liquidity-based pricing to value assessment based on global competitiveness is expected to reshape investor perceptions and enhance the attractiveness of Chinese pharmaceutical innovations [11].

Group 1 - Guolian Minsheng (01456) expects a net profit of RMB 1.129 billion for the first half of 2025, representing a year-on-year increase of approximately 1183% [1] - NIO-SW (09866) saw a rise of over 10% as its sub-brand, Lido, officially launched pre-sales for its new model L90, priced starting at RMB 279,900, which is competitive against similar models [1] - China CNR (01766) rose over 7% following a profit warning, with the rail transit equipment industry showing high demand and Q2 performance exceeding expectations [1] Group 2 - Coal stocks experienced a broad increase, with companies like China Qinfa (00866) and China Shenhua (01088) rising over 4%, driven by strong coal prices amid high temperatures [1] - Zijin Mining (02899) saw a rise of 1.5%, with expected net profit growth of about 54% year-on-year for the first half of the year, although short-term impacts from copper tariffs are anticipated [1] Group 3 - WanGuo Data-SW (09698) increased over 6% after its REIT completed offline inquiries with a subscription multiple of 166 times, indicating significant valuation potential [2] - Hengrui Medicine (01276) rose over 4%, reaching a new high, with expectations that its performance and business development will act as key catalysts [2] - China Shipbuilding Defense (00317) increased over 5% as the merger of two shipbuilding companies approaches completion, with Q2 performance exceeding expectations [2] Group 4 - Bitcoin-related stocks saw significant gains, with Bit Origin (BTOG.US) rising 51.72% and SharpLink Gaming (SBET.US) increasing 17.15%, driven by a surge in Bitcoin prices [3] - Gold stocks strengthened amid geopolitical tensions, with Gold ETF (GLD.US) rising 0.96% and Barrick Mining (B.US) increasing 0.71% [3] Group 5 - British Petroleum (BP.US) rose 3.55% as the company anticipates an increase in Q2 oil production and strong trading performance [7] - Huami Technology (ZEPP.US) surged over 69%, projecting a 30% revenue growth for Q2, marking its first growth in three years [7]

Core Insights - In the first half of 2025, 73 Chinese companies with VC/PE backgrounds successfully went public, achieving an IPO penetration rate of 55.73% for VC/PE institutions [5][14][23] - CICC led the IPO performance by participating in 7 companies, followed by Sequoia China with 6, and Huajin Capital and Junlian Capital with 5 each [5][6] - The total exit return for VC/PE institutions reached 105.76 billion yuan, with an average return multiple of 3.83 times [10][14] Group 1: IPO Performance Analysis - The advanced manufacturing sector had the highest number of IPOs at 16, while the electronic information sector generated the highest exit return of 27.39 billion yuan [10][13] - The Hong Kong Stock Exchange's main board recorded the highest exit return of 58.20 billion yuan [15][16] - In June 2025, the exit return peaked at 34.9 billion yuan, while April saw the highest average return multiple of 9.11 times [10][14] Group 2: Market Trends - The total number of IPOs in the first half of 2025 reached 131, with a total fundraising amount of 130.1 billion yuan, marking a year-on-year increase of 35.05% [25][27] - The Hong Kong Stock Exchange led in both IPO numbers and fundraising amounts, with 40 IPOs raising 86.73 billion yuan [27][29] - The North Exchange had the highest first-day price increase, with 25 companies experiencing a price surge of over 100% [32][33] Group 3: Sector and Regional Analysis - The energy and mining sector saw the highest fundraising amounts, while the consumer sector experienced a significant increase in IPO numbers, doubling compared to the previous year [63][64] - Zhejiang province led in the number of IPOs with 24, while Fujian province topped in fundraising with 33.69 billion yuan [69][72] - The consumer sector's IPO numbers increased by 11, while the medical health sector saw an increase of 9 [63][64] Group 4: Notable IPO Cases - Notable IPOs included Insta360, which achieved a first-day return of 853 times, and Circle, which saw a return of several dozen times on its first day [20][22] - The tea brand Bawang Chaji went public on NASDAQ, with XVC's investment yielding over 100 times return [20][22] - The top five IPOs by fundraising in the first half of 2025 included Ningde Times, Haitian Flavoring, and Heng Rui Medicine, with amounts exceeding 32.78 billion yuan, 9.26 billion yuan, and 9.08 billion yuan respectively [80][82]

Group 1 - The innovative drug sector continues to show strong performance, with significant stock price increases for companies such as Boan Biologics (up 18.68% to HKD 17.66), Hengrui Medicine (up 7.76% to HKD 77.8), and others [1] - The National Healthcare Security Administration has initiated the adjustment application for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, as well as a new commercial health insurance innovative drug catalog [1] - Recent measures issued by the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, indicating a positive outlook for the innovative drug industry and its supply chain [1] Group 2 - The pharmaceutical sector's innovative drugs remain robust, driven by improved biotech investment and supportive domestic policies, which enhance demand expectations for preclinical research [2] - WuXi AppTec's semi-annual performance forecast exceeded expectations, serving as a catalyst for the sector [2] - Investment opportunities in innovative drugs are highlighted, particularly in dual/multi-antibody drugs for various cancers and chronic disease treatments that address unmet clinical needs [2]

Group 1 - The Hong Kong stock market for innovative drugs saw a significant rise in early trading, indicating strong investor interest in the sector [1] - WuXi AppTec (02359.HK) reported a positive earnings forecast, leading to a more than 10% increase in its stock price [1] - WuXi Biologics (02268.HK) experienced a stock price increase of over 7%, reflecting positive market sentiment [1] Group 2 - Other companies in the sector, such as Baoneng Biotech (06955.HK) and Hengrui Medicine (01276.HK), also saw their stock prices rise, indicating a broader trend in the innovative drug market [1]

Investment Rating - The report initiates coverage of Hengrui Pharma's H-shares and resumes coverage of A-shares, both with an Overweight (OW) rating, with H-shares being the preferred stock [1][43]. Core Insights - Hengrui Pharma is positioned to benefit from an improving domestic policy environment and accelerated globalization, which has not yet been fully reflected in the market [1]. - The company is recognized for its extensive and balanced product portfolio, with a strong pipeline across various therapeutic areas, including oncology, metabolic and cardiovascular diseases, immunology, and respiratory diseases [3][12]. - Hengrui is expected to receive approvals for 5, 5, and 11 new drugs in 2025, 2026, and 2027, respectively, totaling 47 NDA/BLA approvals from 2025 to 2027 [3][10]. Summary by Sections Market Potential - The global pharmaceutical market is valued at $1.47 trillion, approximately 6.6 times the size of the Chinese domestic market, with a projected CAGR of 5.7% from 2023 to 2028 [3][32]. - Hengrui has completed 14 licensing deals since 2018, with a total transaction value of $15 billion, indicating strong interest from global biopharma companies in assets from China [3][32]. Financial Projections - The target price for H-shares is HK$78, representing a 45% upside, while the target price for A-shares is RMB 71, representing a 37% upside [7][43]. - Revenue and net profit are projected to grow at CAGRs of 18% and 24%, respectively, from 2024 to 2027 [4][37]. - Innovative drug sales are expected to grow at a CAGR of 34% from 2024 to 2027, contributing to 74% of total drug sales by 2027 [38][40]. Product Pipeline - Hengrui has developed a comprehensive pipeline of innovative drugs, with a focus on key disease areas and a one-stop solution for various subtypes and treatment needs [19][21]. - The company is advancing multiple GLP-1 products targeting the $100 billion global diabetes market, with competitive clinical data supporting their efficacy [19][20]. Valuation Analysis - The DCF valuation method yields a target price of HK$78 for H-shares and RMB 71 for A-shares, with a reasonable premium due to Hengrui's leading position and growth potential [4][43]. - The SOTP analysis indicates that the contribution of globalization opportunities to total value is still conservative, accounting for only 13% of the total estimated value [4][43].